Glass Pharms cultivate for the UK medicines market. This requires us to grow to exacting British standards for both compliance and quality. We supply year round to meet the demand of UK patient needs with fanatical quality assurance and local accountability. Currently, almost all medical cannabis that is supplied to patients in the UK is imported, with inconsistency of quality and supply.
Glass Pharms have the first UK commercial licence granted by the Home Office to supply High-THC cannabis flower to lawful third parties, such as pharmaceutical companies. This will allow the company to grow medical cannabis to the correct regulatory standards for onward supply to UK pharmacies and clinics.
We never lose sight of the fact that our products are intended for use by patients and we listen to their needs. Our cultivation is clinician-led and we use precision chemotypes that have proven efficacy in the real world. World leading biosecurity and testing ensure our products are free from contaminants like heavy metals, fungi and mould.
British-based cultivation means no added importation costs, or supply chain issues for medicines created from our products, enabling cost savings to be passed on to patients.
Consistency is key in growing plants for use in human medicines. In our proprietary cultivation process, more than 10 different growing factors are controlled for using AI. This extraordinary control over conditions means that the end product is consistent time and time again. We use the latest in energy efficient agricultural glasshouse technology and innovation from our partners in the Netherlands, combined with British scientific know-how to ensure world-leading results.
Further National Health-Service Information on